Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Breast Neoplasms 2Neoplasm Metastasis 1Hormone-receptor-positive Breast Cancer 1Hereditary Breast and Ovarian Cancer Syndrome 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 44Paclitaxel 41Cyclophosphamide 21Topotecan 19Cisplatin 18Peripheral Blood Stem Cell Transplantation 15Filgrastim 15Docetaxel 15Gemcitabine 13Bevacizumab 13liposomal doxorubicin 11Hyperthermic Intraperitoneal Chemotherapy 11sargramostim 9Therapeutics 8Immunohistochemistry 8Psychiatric Rehabilitation 7Drug Therapy 7Amifostine 7pembrolizumab 6olaparib 6Taxes 6Surveys and Questionnaires 6Melphalan 6Flow Cytometry 6Early Intervention, Educational 6Chemotherapy, Adjuvant 6niraparib 5denileukin diftitox 5Surgical Procedures, Operative 5Immunoenzyme Techniques 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Ovarian Epithelial × Ovariectomy × Clear all
NCT00084370 2013-08-22

Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy

University of Alabama at Birmingham

Phase NA Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡